SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-054726
Filing Date
2024-05-07
Accepted
2024-05-07 17:05:29
Documents
11
Period of Report
2024-05-01
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K aktx-20240501.htm   iXBRL 8-K 54350
  Complete submission text file 0000950170-24-054726.txt   279199

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20240501.xsd EX-101.SCH 97461
14 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20240501_htm.xml XML 6056
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 24923075
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)